Mersana Therapeutics, Inc.

Historical 13F Holders

Symbol
MRSN
CUSIP
59045L106
All holders as of
Q4 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 59045L106 since 12/18/2024, largest first.

Filer % of Class Filed
Nextech Crossover I GP S.a r.l. 13G/A
10.4% 12/26/2024
Event 12/20/2024
Vanguard Group Inc 13G/A 6.7% 4/30/2025
Event 3/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
BlackRock, Inc. 13G/A 3.0% 7/17/2025
Event 6/30/2025
Venrock Healthcare Capital Partners III, L.P. 13G/A
2.9% 5/15/2025
Event 3/31/2025
EcoR1 Capital, LLC 13G/A
0% 5/15/2025
Event 3/31/2025
Schonfeld Strategic Advisors LLC 13G/A 0% 2/17/2026
Event 12/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q4 3 99.0 $2.86 k
2025 Q3 7 56.1 k $412 k
2025 Q2 87 77.2 M $22.8 M
2025 Q1 115 87.9 M $30.2 M
2024 Q4 142 104 M $149 M
2024 Q3 126 120 M $226 M
2024 Q2 131 118 M $238 M
2024 Q1 134 125 M $559 M
2023 Q4 114 118 M $273 M
2023 Q3 136 114 M $144 M
2023 Q2 177 113 M $370 M
2023 Q1 173 107 M $439 M
2022 Q4 160 107 M $629 M
2022 Q3 158 92.7 M $627 M
2022 Q2 133 88.3 M $408 M
2022 Q1 136 80.9 M $323 M
2021 Q4 130 70.4 M $438 M
2021 Q3 119 68.7 M $648 M
2021 Q2 139 70.6 M $958 M
2021 Q1 146 70.1 M $1.14 B
2020 Q4 169 69.1 M $1.84 B
2020 Q3 151 68.7 M $1.28 B
2020 Q2 147 65.8 M $1.54 B
2020 Q1 87 40.5 M $236 M
2019 Q4 72 36.0 M $206 M
2019 Q3 77 38.5 M $60.8 M
2019 Q2 80 40.0 M $162 M
2019 Q1 67 37.0 M $194 M
2018 Q4 50 17.3 M $70.5 M
2018 Q3 51 19.9 M $199 M
2018 Q2 54 19.2 M $342 M
2018 Q1 57 18.7 M $296 M
2017 Q4 50 17.2 M $283 M
2017 Q3 42 17.5 M $302 M
2017 Q2 29 17.0 M $236 M